Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Malcolm Lloyd-Smith sold 9,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 7th. The stock was sold at an average price of $110.01, for a total transaction of $990,090.00. Following the transaction, the insider now owns 21,018 shares in the company, valued at $2,312,190.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of NASDAQ:NBIX traded up $1.75 during mid-day trading on Monday, hitting $90.02. The company had a trading volume of 813,400 shares, compared to its average volume of 794,759. The firm has a market capitalization of $8.00 billion, a P/E ratio of -55.57, a P/E/G ratio of 22.58 and a beta of 0.91. Neurocrine Biosciences, Inc. has a one year low of $68.22 and a one year high of $126.98.
Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Monday, November 5th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.04. Neurocrine Biosciences had a net margin of 2.40% and a return on equity of 2.54%. The company had revenue of $151.80 million during the quarter, compared to analyst estimates of $151.51 million. During the same quarter in the previous year, the business posted ($0.13) EPS. Neurocrine Biosciences’s revenue for the quarter was up 149.7% compared to the same quarter last year. Equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 0.19 EPS for the current fiscal year.
A number of equities research analysts recently weighed in on the stock. Stifel Nicolaus boosted their price target on shares of Neurocrine Biosciences from $137.00 to $142.00 and gave the stock a “buy” rating in a research note on Thursday, September 20th. Oppenheimer set a $140.00 target price on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research note on Tuesday, September 4th. Leerink Swann began coverage on shares of Neurocrine Biosciences in a research note on Monday, November 12th. They issued a “market perform” rating and a $110.00 target price for the company. Piper Jaffray Companies set a $111.00 target price on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research note on Tuesday, November 6th. Finally, Cantor Fitzgerald set a $150.00 price target on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Thursday, September 20th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seventeen have given a buy rating to the company. Neurocrine Biosciences has an average rating of “Buy” and a consensus target price of $124.88.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.
Featured Story: Why Dividend Stocks May Be Right for You
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.